This study is funded by the Mayo Clinician Investigator Award to DL Packer.
Long-Term Outcome of Atrial Fibrillation Ablation: Impact and Predictors of Very Late Recurrence
Article first published online: 24 MAY 2010
© 2010 Wiley Periodicals, Inc.
Journal of Cardiovascular Electrophysiology
Volume 21, Issue 10, pages 1071–1078, October 2010
How to Cite
WOKHLU, A., HODGE, D. O., MONAHAN, K. H., ASIRVATHAM, S. J., FRIEDMAN, P. A., MUNGER, T. M., CHA, Y.-M., SHEN, W.-K., BRADY, P. A., BLUHM, C. M., HAROLDSON, J. M., HAMMILL, S. C. and PACKER, D. L. (2010), Long-Term Outcome of Atrial Fibrillation Ablation: Impact and Predictors of Very Late Recurrence. Journal of Cardiovascular Electrophysiology, 21: 1071–1078. doi: 10.1111/j.1540-8167.2010.01786.x
Dr. Asirvatham receives honoraria from Boston Scientific, St. Jude Medical, Biotronik, and Medtronic and serves as a consultant for Sanofi-Aventis. Dr. Friedman receives research funding from Bard, St. Jude Medical, Medtronic, Boston Scientific, and Pfizer; intellectual property rights for Bard EP, Hewlett Packard, Medical Positioning, Inc., Aegis Medical, and NeoChord; and has served as a speaker/consultant for Medtronic, Boston Scientific, and St. Jude Medical. Dr. Packer in the past 12 months has provided consulting services for Biosense Webster, Inc., Boston Scientific, CyberHeart, Medtronic, Inc., nContact, Sanofi-Aventis, St. Jude Medical, and Toray Industries. Dr. Packer received no personal compensation for these consulting activities. Dr. Packer receives research funding from the NIH, Medtronic, Inc., CryoCath, Siemens AG, EP Limited, St. Jude Medical, Minnesota Partnership for Biotechnology and Medical Genomics/ University of Minnesota, Biosense Webster, Inc. and Boston Scientific. Mayo Clinic and Drs. Packer and R. Robb (not a contributing author) have a financial interest in mapping technology. In accordance with the Bayh-Dole Act, this technology has been licensed to St. Jude Medical, and Mayo Clinic and Drs. Packer and Robb have received annual royalties greater than $10,000, the federal threshold for significant financial interest. Other authors report no potential conflicts.
- Issue published online: 24 MAY 2010
- Article first published online: 24 MAY 2010
- Manuscript received 14 November 2009; Revised manuscript received 25 February 2010; Accepted for publication 12 March 2010.
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.